Cardiothoracic & vascular anesthesia
Levosimendan in patients undergoing extracorporeal membrane oxygenation after cardiac surgery: an emulated target trial using observational data
Main finding · Time to successful VA-ECMO weaningResult — go to the resultHR for successful ECMO weaning 0.91 CI 0.57–1.45Authors' conclusion
Using the emulated target trial framework, this study did not find any association of levosimendan treatment and ECMO weaning success after postcardiotomy cardiogenic shock.
Study context
- Population
- Patients with refractory postcardiotomy cardiogenic shock assisted with veno-arterial extracorporeal membrane oxygenation (VA-ECMO), surgical ICU at La Pitié-Salpêtrière Hospital, 2016–20191,434 patient copies
- Participants
- 239 patients
- Exposure
- Levosimendan vs no levosimendan during VA-ECMO
- Outcome
- Time to successful ECMO weaning
Methodological detailssequential nested trials, multivariable adjustment, single-centre
- Sequential nested trials
- Multivariable adjustment
- Single-centre
Main finding
Time to successful VA-ECMO weaning
HR for successful ECMO weaning
0.91
CI 0.57–1.45
P = 0.659
Levosimendan vs No levosimendan
HR for successful ECMO weaning 0.91 (CI 0.57–1.45); P = 0.659
As reported in the abstract
Observational data: associations, not effects.
Secondary outcomes
| Outcome | OR (CI) | P value | |
|---|---|---|---|
| 30-day mortality | 1.03 (0.52–2.03) | P = 0.940 | |
| 1-year mortality | 1.00 (0.53–1.89) | P = 0.999 | |
| 0.512Odds ratio (log scale) |
Original publication
Levosimendan in patients undergoing extracorporeal membrane oxygenation after cardiac surgery: an emulated target trial using observational data. Crit Care. Published 7 February 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →